Cabaletta: Additional Fast Track in in Dermatomyositis and Systemic Sclerosis

– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development and review of CABA-201 for the treatment of these autoimmune diseases –

https://www.globenewswire.com/news-release/2024/01/08/2805284/0/en/Cabaletta-Bio-Receives-Additional-FDA-Fast-Track-Designations-for-CABA-201-in-Dermatomyositis-and-Systemic-Sclerosis.html